A new era of personalised cancer treatments - FT中文網
登錄×
電子郵件/用戶名
密碼
記住我
請輸入郵箱和密碼進行綁定操作:
請輸入手機號碼,透過簡訊驗證(目前僅支援中國大陸地區的手機號):
請您閱讀我們的用戶註冊協議私隱權保護政策,點擊下方按鈕即視爲您接受。
FT商學院

A new era of personalised cancer treatments

As incidence rises, breakthroughs in oncology show the value of research funding
00:00

{"text":[[{"start":9.17,"text":"Good news is flowing from the world’s cancer labs. "},{"start":12.187000000000001,"text":"Researchers are reporting encouraging clinical trial results for a diversity of novel treatments, including individualised cancer vaccines, as well as new diagnostic techniques. "},{"start":21.692,"text":"Various forms of immunotherapy — adapting the patient’s immune system to destroy cancer cells — are proving remarkably successful at extending survival times of some people with refractory tumours. "}],[{"start":32.53,"text":"One reason for the rapid progress is that cancer research has been well funded by industry, governments and charities in comparison with other diseases. "},{"start":40.472,"text":"Almost 40 per cent of all pharmaceutical R&D investment is directed at clinical oncology — making it the leading field for precision medicine, with diagnostics and drugs tailored to the individual characteristics of patients. "}],[{"start":52.510000000000005,"text":"This encouraging lesson about the productivity of research funding has not been lost on scientists working on different diseases, such as dementia and infections, where there is much unmet medical need but relatively less investment. "},{"start":64.302,"text":"They are right to point to cancer as an example of what can be achieved with more R&D resources. "}],[{"start":70.25,"text":"Moving cancer research breakthroughs rapidly into regular clinical practice will require agile regulators and responsive healthcare providers. "},{"start":77.742,"text":"They must provide not only appropriate treatment facilities, but diagnostic services to detect tumours as early as possible when chances of a cure are highest. "}],[{"start":87.03,"text":"The new wave of personalised treatments will be expensive when first introduced; immunotherapies often cost more than $100,000 per patient. "},{"start":95.259,"text":"Pharma companies will inevitably come under pressure to cut what their critics may portray as exorbitant pricing. "},{"start":100.952,"text":"While drug prices must be subject to some control, the industry’s return on investment should remain high enough to maintain its large, productive cancer research effort. "},{"start":109.644,"text":"Costs of new medical technologies do come down over time as they are applied more extensively. "}],[{"start":115.5,"text":"Faster diagnosis and better treatments are needed more than ever, as the incidence of cancer continues to rise globally. "},{"start":121.94200000000001,"text":"Disturbingly, cases are growing most rapidly among younger people, for reasons that scientists are only just beginning to understand — and which require urgent investigation. "},{"start":131.272,"text":"Cancer rates in 25- to 49-year-olds increased by 24 per cent since 1995, according to the charity Cancer Research UK. "},{"start":139.727,"text":"Although cancer remains largely an affliction of old age, and under-50s still account for no more than 10 per cent of all patients, they represent a much larger proportion of years of healthy life lost to the disease. "}],[{"start":150.98,"text":"Experts believe the rapid increase in obesity in recent decades is one factor driving the growth of tumours such as breast and colorectal cancer among the young. "},{"start":159.384,"text":"Data presented at the recent American Society of Clinical Oncology conference in Chicago suggests that taking the popular weight-loss drugs Ozempic and Wegovy would reduce the risk of developing many common tumours — though, as public health campaigners point out, it would be preferable to tackle obesity by changing people’s diets rather than by medication. "},{"start":177.10199999999998,"text":"Beyond obesity, scientists are looking for carcinogenic signals among the many environmental and lifestyle changes that have taken place over recent decades. "}],[{"start":185.67,"text":"As the disease becomes more prevalent, people are living for longer on average after diagnosis, though progress is currently slow. "},{"start":192.69899999999998,"text":"Human biology means that cancer will always be with us. "},{"start":195.94199999999998,"text":"But the new diagnostic tools and treatments emerging from the world’s labs promise to accelerate the extension of survival time — and make oncology a shining example of the value of biomedical research spending. "}],[{"start":206.75,"text":""}]],"url":"https://creatives.ftacademy.cn/album/158108-1717832601.mp3"}

版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。

川普和海湖莊園的力量

這位前房地產開發商非常瞭解如何將建築和空間有效地用作宣傳。

爲2024年的世界感到高興的十個理由

從巴黎聖母院的修復到《抑制熱情》的大結局,這一年其實並不算太糟。

2025年德國大選:主要的競選承諾是什麼?

各大政黨提出了截然不同的計劃,以重振歐洲最大經濟體的命運。

「市場恐慌」:巴西財政赤字導致貨幣跌至新低

總統在面臨其第三個任期內的最大挑戰。

川普過渡團隊尋求在「第一天」讓美國退出世衛組織

美國的迅速退出將使全球衛生機構失去主要資金來源,並削弱其應對緊急情況的能力。

谷歌推動重新確立人工智慧領域的領先地位,提振了投資者信心

在經歷了過山車般的一年之後,人工智慧和量子計算領域的一系列突破帶來了轉機。
設置字型大小×
最小
較小
默認
較大
最大
分享×